Cardiac Rhythm Management Devices – Market Insights – United States

The US CRM device market is projected to grow slightly through 2035, driven by the increasing adoption of innovative devices, particularly extravascular ICDs, and CSP-capable pacing and defibrillation leads. These product innovations, supported by positive clinical evidence, are driving market growth, and these devices are gaining traction as the new standard of care.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for CRM devices in the US from 2019 through 2035.

The adoption of innovative devices will drive growth in the US CRM device market.

What level of growth is forecasted for novel devices like CSP leads and extravascular ICDs?

What factors are likely to influence the uptake of these devices?

How has the rising adoption of CSP leads impacted the overall market?

The generation of clinical data will be an important competitive factor for disruptive CRM devices.

Which clinical trials are ongoing in the CRM device market and may lead to new approvals or indication expansions?

What regulatory and reimbursement changes are expected due to clinical evidence?

How will ongoing clinical trials alter the market share dynamics of different device segments?

Some segments of the CRM device market are being negatively impacted by new innovations.

How have traditional pulse generators, leads, and lead extraction devices been impacted by new innovations in leadless pulse generators and CSP-capable leads?

Which competitors will be most negatively impacted by these innovations, and what strategies should be employed to avoid the impact of disruptive technology?

What combinations of devices will start to be used concurrently to address gaps in product features to treat larger patient populations?